Osporil (Zoledronic Acid)

Zoledronic Acid, the active ingredient in Osporil, is a bisphosphonate presented as a 4 mg/5 ml solution for intravenous use. It is used to treat bone loss conditions such as osteoporosis in post‑menopausal women and to reduce skeletal‑related events in patients with bone metastases. GNH USA supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Osporil is a bisphosphonate that acts on bone‑remodelling disorders and related complications.

- Osteoporosis: reduces the risk of vertebral and hip fractures in post‑menopausal women and men at high risk. - Bone metastases from solid tumours: lowers the incidence of skeletal‑related events such as pathological fractures and spinal cord compression. - Hypercalcaemia of malignancy: rapidly lowers elevated serum calcium levels in cancer patients. - Paget’s disease of bone: normalises bone turnover and alleviates bone pain. - Chronic kidney disease‑related mineral bone disorder: helps control secondary hyperparathyroidism and bone turnover. - Adjuvant therapy after breast cancer surgery: decreases the risk of bone loss associated with aromatase‑inhibitor treatment.

Zoledronic acid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Acute‑phase flu‑like symptoms: fever, myalgia, arthralgia, and headache shortly after infusion. - Gastro‑intestinal discomfort: nausea, abdominal pain, dyspepsia. - Musculoskeletal pain: transient bone or joint pain. - Transient hypocalcaemia: mild drops in serum calcium levels. - Injection‑site reactions: erythema or mild swelling at the infusion site.

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ): exposed necrotic bone in the maxillofacial region. - Atypical femoral fractures: low‑energy subtrochanteric or femoral shaft fractures. - Severe hypocalcaemia: clinically significant calcium depletion requiring medical intervention. - Renal impairment: acute kidney injury or worsening of pre‑existing renal dysfunction. - Anaphylaxis: rare systemic hypersensitivity reactions.

Before initiating therapy with zoledronic acid, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

- Renal function: evaluate serum creatinine and calculate eGFR; adjust or avoid use if eGFR < 30 ml/min/1.73 m². - Calcium and vitamin D status: correct deficiencies prior to infusion to reduce hypocalcaemia risk. - Dental health: obtain dental evaluation and treat active infections before treatment to lower ONJ risk. - Concomitant medications: review use of nephrotoxic drugs, NSAIDs, and high‑dose corticosteroids. - Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Zoledronic acid may interact with several medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increase risk of renal injury. - High‑dose vitamin D analogues: potentiate hypocalcaemia. - Bisphosphonate combination therapy: additive effects on bone turnover and renal function.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate calcium loss. - Corticosteroids: increase risk of osteonecrosis of the jaw. - Antacids containing aluminium or magnesium: can affect absorption of calcium supplements used alongside therapy.